* Seattle Genetics announces European commission approval of
adcetris (brentuximab vedotin) as consolidation treatment in
post-transplant hodgkin lymphoma

Source text for Eikon:
Further company…

The post BRIEF-Seattle Genetics says European Commission approves adcetris for post-transplant hodgkin lymphoma appeared first on NASDAQ.